• Definium Therapeutics backed a newly signed White House executive order aimed at accelerating research, development, and responsible access to treatments for serious mental illness, including psychedelic medicines.
• CEO Rob Barrow said psychedelic medicines could become meaningful new options for patients.
• Definium highlighted its late-stage clinical program for DT120 (lysergide tartrate) in generalized anxiety disorder, major depressive disorder.
• Company said streamlined regulatory pathways, cross-agency coordination could speed translation of innovation into care.
• Definium emphasized FDA evidence-based review as key route to delivering psychedelic therapies safely to patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260418158429) on April 18, 2026, and is solely responsible for the information contained therein.